GlassScriptPhysician profile
Matthew L Rennels
NPI 1043571037
$2,352.94
in general payments reported to CMS, 2019-2025
34 companies · $480 in 2025
The $480 reported for 2025 was more than what 82% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $134 · 2021: $471 · 2022: $349 · 2023: $133 · 2024: $270 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $564.76 | 2019-2025 | |
| Abbvie INC. | $234.81 | 2021-2025 | |
| Pacira Therapeutics, INC. | $219.51 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $150.61 | 2022 | |
| Trice Medical, INC. | $125.35 | 2025 | |
| Tenex Health INC. | $115.16 | 2021 | |
| Allergan, INC. | $108.55 | 2019-2021 | |
| Novo Nordisk INC | $97.42 | 2019-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $69.77 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $64.66 | 2021 | |
| Axsome Therapeutics, INC. | $54.33 | 2023-2024 | Auvelity |
| Scilex Pharmaceuticals INC. | $51.60 | 2019-2020 | |
| Merz North America, INC. | $46.89 | 2019 | |
| Heartflow, INC. | $38.25 | 2025 | |
| Collegium Pharmaceutical, INC. | $37.21 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $31.16 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $28.35 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.31 | 2020-2022 | |
| Ossur Americas, INC. | $27.94 | 2024 | Miami J |
| Kowa Pharmaceuticals America, INC. | $27.75 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.13 | 2019 | |
| Abbott Laboratories | $21.00 | 2022 | |
| Almatica Pharma LLC | $20.81 | 2021 | |
| Phadia US INC. | $19.09 | 2022 | |
| Amgen INC. | $19.06 | 2019 | |
| Ge Healthcare | $17.60 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.44 | 2025 | |
| Grt US Holding, INC. | $15.75 | 2022 | |
| Avanos Medical | $13.95 | 2019 | |
| Daiichi Sankyo INC. | $13.92 | 2019 | |
| Lilly USA, LLC | $13.58 | 2020 | |
| Depuy Synthes Sales INC. | $12.91 | 2020 | |
| Glaxosmithkline, LLC. | $11.85 | 2022 | |
| Corium, LLC | $10.46 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Rennels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.